A recent paper published in Communications Chemistry, led by research from UB Chemistry, discusses the structures and properties of EGFR bivalent inhibitors. This sheds light on ways to design new drugs more effectively. The findings are expected to influence practices across diverse small-molecule drug development programs in both academic and industrial settings, while also laying the foundation for advanced targeted cancer therapies.